These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38506362)

  • 1. [DIAGNOSIS AND TREATMENT OF ELEVATED LIPOPROTEIN(A) IN ISRAEL: CONSENSUS STATEMENT FROM THE ISRAEL SOCIETY FOR RESEARCH, PREVENTION AND TREATMENT OF ATHEROSCLEROSIS AND ISRAEL SOCIETY FOR CLINICAL LABORATORY SCIENCES].
    Zafrir B; Durst R; Henig C; Henkin Y; Itzhakov E; Kaplan M; Gavish D
    Harefuah; 2024 Mar; 163(3):185-190. PubMed ID: 38506362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
    Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The re-emergence of lipoprotein(a) in a broader clinical arena.
    Tsimikas S
    Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky M; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Eur Heart J; 2022 Oct; 43(39):3925-3946. PubMed ID: 36036785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA).
    Chiesa G; Zenti MG; Baragetti A; Barbagallo CM; Borghi C; Colivicchi F; Maggioni AP; Noto D; Pirro M; Rivellese AA; Sampietro T; Sbrana F; Arca M; Averna M; Catapano AL
    Nutr Metab Cardiovasc Dis; 2023 Oct; 33(10):1866-1877. PubMed ID: 37586921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations.
    Ward NC; Watts GF; Bishop W; Colquhoun D; Hamilton-Craig C; Hare DL; Kangaharan N; Kostner KM; Kritharides L; O'Brien R; Mori TA; Nestel PJ; Nicholls SJ; Psaltis PJ; Raffoul N; White HD; Sullivan DR
    Heart Lung Circ; 2023 Mar; 32(3):287-296. PubMed ID: 36707360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lp(a) in the Pathogenesis of Aortic Stenosis and Approach to Therapy with Antisense Oligonucleotides or Short Interfering RNA.
    Di Costanzo A; Indolfi C; Franzone A; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
    Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
    J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study.
    Wang WG; He YF; Chen YL; Zhao FM; Song YQ; Zhang H; Ma YH; Guan X; Zhang WY; Chen XL; Liu C; Cong HL
    J Int Med Res; 2016 Aug; 44(4):865-74. PubMed ID: 27278556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
    Vinci P; Di Girolamo FG; Panizon E; Tosoni LM; Cerrato C; Pellicori F; Altamura N; Pirulli A; Zaccari M; Biasinutto C; Roni C; Fiotti N; Schincariol P; Mangogna A; Biolo G
    Int J Environ Res Public Health; 2023 Sep; 20(18):. PubMed ID: 37754581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
    Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
    J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease.
    Nestel P; Loh WJ; Ward NC; Watts GF
    J Clin Endocrinol Metab; 2022 Nov; 107(11):e4281-e4294. PubMed ID: 36108076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.
    Rehberger Likozar A; Zavrtanik M; Šebeštjen M
    Ann Med; 2020 Aug; 52(5):162-177. PubMed ID: 32453609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic.
    Chakraborty A; Pang J; Chan DC; Barnett W; Woodward AM; Vorster M; Watts GF
    Clin Cardiol; 2021 Jun; 44(6):805-813. PubMed ID: 33955565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Vuorio A; Watts GF; Kovanen PT
    Atherosclerosis; 2019 Feb; 281():25-30. PubMed ID: 30616181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.